XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Testing revenue $ 213.3 $ 191.9 $ 627.0 $ 556.6
Costs and expenses:        
Cost of testing revenue 63.5 57.6 192.5 174.6
Research and development expense 28.5 24.0 81.2 67.7
Selling, general, and administrative expense 139.1 136.1 424.0 428.5
Legal settlements 0.0 34.3 0.0 111.8
Goodwill and long-lived asset impairment charges 2.2 0.0 13.8 0.0
Total costs and expenses 233.3 252.0 711.5 782.6
Operating loss (20.0) (60.1) (84.5) (226.0)
Other income (expense):        
Interest income 0.4 0.6 1.4 1.8
Interest expense (0.8) (1.0) (2.1) (2.0)
Other (0.8) (0.7) 0.8 (3.7)
Total other income (expense), net (1.2) (1.1) 0.1 (3.9)
Loss before income tax (21.2) (61.2) (84.4) (229.9)
Income tax expense 0.9 0.1 0.4 2.2
Net loss $ (22.1) $ (61.3) $ (84.8) $ (232.1)
Net loss per share:        
Basic (dollars per share) $ (0.24) $ (0.75) $ (0.94) $ (2.84)
Diluted (dollars per share) $ (0.24) $ (0.75) $ (0.94) $ (2.84)
Weighted average shares outstanding:        
Basic (shares) 90.9 81.9 90.5 81.6
Diluted (shares) 90.9 81.9 90.5 81.6
Revenue from contract with customer, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member]
Cost, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member]